Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer (Q37768460)

22 August 2017

1 reference

title

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer (English)

1 reference

22 August 2017

1 reference

Athanasios Kotsakis

1

1 reference

PubMed ID

20586711

22 August 2017

Vassilis Georgoulias

series ordinal

2

1 reference

PubMed ID

20586711

22 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

14

1 reference

22 August 2017

2363-2389

1 reference

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Novel combinations based on epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Akt signaling and cancer: surviving but not moving on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

STAT3 as a therapeutic target in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor biology in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Molecular biology of epidermal growth factor receptor inhibition for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Role of an anti-epidermal growth factor receptor in treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Mechanisms of cutaneous toxicities to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

K-ras mutations in non-small-cell lung carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.498581

10.1517/14656566.2010.498581

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20586711